Saroglitazar Magnesium not checked

Zydus Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
in other
Next date
Phase 3 trial completes
Trials
5 active
17 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program”In the company’s words, NCT06427395 on ClinicalTrials.gov
Tested for
Primary Biliary Cholangitis (3 trials), Cholestatic Liver Disease (2 trials), Hepatic Impairment, Cirrhosis
Main trialPhase 3
“Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis”In the company’s words, NCT06427395 on ClinicalTrials.gov
Other names
Saroglitazar · Not any

Other drugs for Primary Biliary Cholangitis

All 7 drugs for Primary Biliary Cholangitis

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 18 Apr 2027 Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Phase 3Recruiting Jul 2028 Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy
Phase 3Recruiting Nov 2032 Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
Phase 1Recruiting 31 Dec 2026 Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Phase 1Recruiting 31 Dec 2026 Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Phase 4Unknown 10 Jan 2025 A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
Phase 2/3Completed 30 Apr 2025 Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Phase 2Completed 22 Aug 2019 Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Phase 2Completed 20 Mar 2020 Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
Phase 2Completed 7 Aug 2020 Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
Phase 2Completed 13 Dec 2021 Safety, Tolerability, and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease (NAFLD)
Phase 2Terminated 2 Oct 2023 Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
Phase 2Suspended Dec 2023 Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Phase 2Terminated 28 Oct 2024 Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
Phase 2Completed 12 Sep 2025 Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Phase 1Completed 21 Mar 2022 Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function
Phase 1Completed 28 May 2024 A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects with Severe Renal Impairment and Normal Renal Function
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Saroglitazar Magnesium

Following is part of Solo: you see every change to Saroglitazar Magnesium the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in